From: Fertility preservation after gonadotoxic treatments for cancer and autoimmune diseases
Characteristics | GnRH antagonist | PPOS | P-value | ||
---|---|---|---|---|---|
Number of participants (n) | 16 | Â | 11 | Â | Â |
Number of cycles (n) | 18 | Â | 15 | Â | Â |
Age (years) | 34 | (30–37) | 33 | (32–35) | 0.979 |
AFC | 10 | (5–19) | 9 | (6–15) | 0.888 |
Basal FSH (IU/L) | 6.1 | (5.8–9.4) | 6.1 | (4.2–8.9) | 0.663 |
AMH (ng/ml) | 1.96 | (1.32–4.77) | 1.60 | (0.99–3.65) | 0.287 |
Disease type [n (%)]a | |||||
 Haematological cancers | 2 | (11.1) | 0 | (0.0) |  |
 Breast cancer | 13 | (72.2) | 8 | (53.3) |  |
 Gynecological cancers | 2 | (11.1) | 2 | (13.3) |  |
 Sarcoma | 0 | (0.0) | 0 | (0.0) |  |
 Other cancers | 0 | (0.0) | 4 | (26.7) |  |
 Systemic autoimmune diseases | 1 | (5.6) | 1 | (6.7) |  |
Stimulation start timing/ stimulation phase [n (%)]b | |||||
 Normal (Day 1–4) | 13 | (72.2) | 5 | (33.3) |  |
 Random (Follicular phase, Luteal phase) | 5 | (27.8) | 8 | (53.3) |  |
 DuoStim | 0 | (0.0) | 2 | (13.3) |  |
Gonadotrophin | |||||
 Starting dose of Gonadotropin (IU) | 150 | (150–281) | 225 | (188–225) | 0.498 |
 Duration of Gonadotropin use (days) | 10 | (8–10) | 10 | (9–12) | 0.475 |
 Total dosage of Gonadotropin use (IU) | 1800 | (1369–2325) | 2175 | (1725–2700) | 0.319 |
Triggar [n (%)]b | |||||
 hCG or recombinant hCG | 16 | (88.9) | 14 | (93.3) |  |
 GnRHa | 1 | (5.6) | 0 | (0.0) |  |
 Dual triggar | 1 | (5.6) | 1 | (6.7) |  |
 Serum estradiol on trigger day (pmol/L) | 1035 | (762–1464) | 681 | (525–1404) | 0.270 |
Outcome of oocyte retrieval | |||||
 Number of oocyte retrieved (n) | 10 | (6–15) | 8 | (5–11) | 0.414 |
 Number of MII oocytes retrieved (n) | 9 | (4–11) | 8 | (5–10) | 0.810 |
 Number of MI oocytes retrieved (n) | 1 | (0–1) | 0 | (0–1) | 0.196 |
 Number of GV oocytes retrieved (n) | 1 | (0–1) | 0 | (0–0) | 0.051 |
 Mature oocyte rate (%)c | 86.7 | (71.6–99.0) | 100 | (91.0–100) | 0.052 |
Method for fertilisation [n (%)]b | |||||
 Conventional insemination | 2 | (11.1) | 2 | (13.3) |  |
 Intracytoplasmic sperm injection | 1 | (5.6) | 4 | (26.7) |  |
 Split | 4 | (22.2) | 0 | (0.0) |  |
 None | 11 | (61.1) | 9 | (60.0) |  |
Embryological outcome | |||||
 Fertilisation rate (%)d | 60.0 | (50.4–68.9) | 87.5 | (56.3–100) | 0.374 |
 Cleavage developmental rate (%)e | 71.4 | (58.3–100) | 100 | (89.3–100) | 0.237 |
 Blastocyst developmental rate (%)f | 100 | (70.8–100) | 100 | (87.5–100) | 0.694 |
 Frozen embryo (n) | 4 | (3–4) | 5 | (2–6) | 0.768 |